All News

Long-term data from the phase 2 TROG 15.03 FASTRACK II trial support the safety and efficacy of stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Jonathan D. Harper, MD, discusses findings from a secondary analysis of the PUSH trial showing that modest increases in urine volume and lower urine osmolality were associated with reduced kidney stone recurrence, even when patients did not reach the guideline-recommended urine output target.

The approval adds another commercially available source of the PSMA-targeted radiotracer.

Kevin C. Zorn, MD, FRCSC, FACS, discusses the factors that clinicians should consider when selecting among different MIST options for BPH.

In this episode, Amy Pearlman, MD, and Annah J. Vollstedt, MD, discuss emerging innovations in female pelvic medicine, including implantable tibial nerve stimulation, the role of pelvic floor physical therapy, and the future of incontinence care.

In this video, Nicole L. Miller, MD, FACS, discusses her approach to assessing patients after prior treatment failure for benign prostatic hyperplasia.

The addition of aglatimagene and valacyclovir to radiotherapy with or without ADT significantly improved disease-free survival in patients with intermediate- to high-risk localized prostate cancer.

Abigail Keller, MD, shares findings showing that nadofaragene firadenovec is associated with increased urine production during instillation compared with gemcitabine/docetaxel.

Clint D. Bahler, MD, reflects on key prostate cancer themes from AUA 2026, including the shift toward more personalized care.

The primary end point—12-month DFS rate—was 80% (40/50 evaluable patients; 95% CI, 0.67-0.89), with 2 patients pending assessment and 3 not evaluable.

The pivotal trial is assessing the non-inferiority of the Separo Vessel Sealing System vs conventional mucosal cautery vasectomy.

Praful Ravi, MB, BChir, MRCP, discusses results from PSMAtrack, which assessed changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer.

A recap of the FDA submissions and regulatory decisions in urology from May 2026.

Titan Prime will be available in the US via a phased launch beginning in late 2026.

In this episode of Pearls & Perspectives, Amy Pearlman, MD, speaks with Tom Riester of LTR Pharma about the development of a novel intranasal therapy for erectile dysfunction, exploring its potential implications for sexual health, prostate cancer survivorship, and broader engagement in men's health care.

Pedro C. Barata, MD, MSc, FACP, discusses preliminary findings from the phase 3 ProstACT Global study evaluating 177Lu-rosopatamab plus standard of care for patients with mCRPC.

PSA50 response rates were 58.8% overall in Group A (72.7% at 10 MBq), 85.2% overall in Group B (100% at 10 MBq), and 52.5% overall in Group C (56.3% at 10 MBq).

Tanya B. Dorff, MD, FASCO, shares phase 1 data on ABBV-969, an investigational antibody-drug conjugate being explored for metastatic castration-resistant prostate cancer.

"Together with the efficacy and safety results, these PRO findings support the overall benefit-risk profile of perioperative EV plus [pembrolizumab] as the new standard of care in this patient population," said Peter H. O'Donnell, MD.

Kim Chi, MD, highlights findings from a pre-planned analysis of the PLUDO trial examining the impact of crossover on survival outcomes between 177Lu-PSMA-617 vs docetaxel in mCRPC.

The FDA approved cefepime and zidebactam for adult complicated UTI after ENHANCE-1 showed an 89.0% response rate at test of cure.

"Compared to placebo [plus] ADT, apalutamide [plus] ADT showed 9 times more pCR/MRD, a 20% improved MFS, a 29% reduction in prostate cancer recurrence, and a 3-year improvement in time to subsequent therapy," said Mary-Ellen Taplin, MD, FASCO.

Lucia Nappi, MD, PhD, FRCPC, highlights key findings from an interim analysis of SWOG S1823, evaluating miR371 for predicting active germ cell malignancy in patients with early-stage testicular cancer.

Study investigator Gopa Iyer, MD, concluded that LY4052031 represents a promising next-generation Nectin-4 ADC with a distinct payload mechanism that may overcome EV resistance in mUC.

"These data help inform patient decision-making regarding adjuvant therapy and also point to a possible need for supportive services to help survivors after treatment," said Ronald C. Chen, MD, MPH, FASCO, FASTRO.

Alicia K. Morgans, MD, MPH, discusses key findings from the ARACOG study, assessing cognitive outcomes between patients who received darolutamide vs those who received enzalutamide for advanced prostate cancer.

The phase 2 ARACOG trial noted a greater decline in objectively measured cognitive function over 24 weeks among patients who received enzalutamide vs darolutamide for advanced prostate cancer.